Metoprolol

Metoprolol

SCHEMBL41104

COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)C(O)C(O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1

The experimentally established mechanism targets of Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 known ✓ P08588 4/20 0.84
TDP1 Q9NUW8 3/20 1.00
PMP22 Q01453 2/20 1.00
NPY1R P25929 1/20 1.00
NPY2R P49146 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
ADRB2 P07550 3/20 0.84
ADRA1A P35348 2/20 0.84
CYP2D6 P10635 2/20 0.84
NR3C1 P04150 1/20 0.84
CYP2J2 P51589 1/20 0.84
PDE4D Q08499 1/20 0.84
ABCB1 P08183 1/20 0.60
LMNA P02545 2/20 0.60
CNR1 P21554 1/20 0.60
ADRA1D P25100 1/20 0.60
ADRA1B P35368 1/20 0.60
KDM4E B2RXH2 1/20 0.60
CYP1A2 P05177 1/20 0.60
GLA P06280 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Metoprolol SCHEMBL19211129 1.00 TDP1 (1.00) TDP1PMP22NPY1RNPY2RNPSR1
Metoprolol SCHEMBL29995613 1.00 TDP1 (1.00) TDP1PMP22NPY1RNPY2RNPSR1
Metoprolol SCHEMBL1649321 1.00 TDP1 (1.00) TDP1PMP22NPY1RNPY2RNPSR1
Metoprolol SCHEMBL29367290 1.00 TDP1 (1.00) TDP1PMP22NPY1RNPY2RNPSR1
Metoprolol SCHEMBL4881939 1.00 TDP1 (1.00) TDP1PMP22NPY1RNPY2RNPSR1
(S)-Metoprolol SCHEMBL141366 1.00 TDP1 (1.00) TDP1PMP22NPY1RNPY2RNPSR1
Metoprolol SCHEMBL2124595 0.99 TDP1 (0.98) TDP1PMP22NPY1RNPY2RNPSR1
Metoprolol SCHEMBL4879331 0.98 TDP1 (0.96) TDP1PMP22NPY1RNPY2RNPSR1
Metoprolol SCHEMBL28264735 0.97 TDP1 (0.94) TDP1PMP22NPY1RNPY2RNPSR1
(S)-Metoprolol SCHEMBL3123844 0.93 ADRB2 (0.88) TDP1PMP22NPY1RNPY2RNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9615 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4691556-A2 HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF H. Lundbeck A/S (DK) 2026-02-11 EP claimed
US-20250382291-A1 SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS UNIV COLUMBIA (US) 2025-12-18 US claimed
US-20250302887-A1 AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE AOBIOME LLC (US) 2025-10-02 US claimed
EP-4615449-A1 METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS Weinberg, Assa (US) 2025-09-17 EP claimed
US-20250262195-A1 METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS WEINBERG ASSA (US) 2025-08-21 US claimed
US-20250264469-A1 METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME CHILDREN'S HOSPITAL MEDICAL CENTER 2025-08-21 US claimed
EP-4598526-A1 METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS Weinberg, Assa (US) 2025-08-13 EP claimed
US-20250228831-A1 METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS WEINBERG ASSA (US) 2025-07-17 US claimed
US-20250223370-A1 METHODS OF TREATING DISORDERS USING ANTI-NATRIURETIC PEPTIDE RECEPTOR 1 (NPR1) ANTIBODIES NOVARTIS AG (CH) 2025-07-10 US claimed
WO-2025131019-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) 2025-06-26 WO claimed
US-5260066-A Cryogel bandage containing therapeutic agent SRCHEM INCORPORATED (US) 1993-11-09 US claimed
WO-1993015725-A1 COMPOSITIONS AND PROCESSES FOR THE SUSTAINED RELEASE OF DRUGS PITMAN-MOORE, INC. (US) 1993-08-19 WO claimed
EP-0487237-A1 New optically active metoprolol tartrate salts, and method of preparing them, and method of preparing optically active metoprolol from the tartrate salts Nitto Denko Co. Ltd. (JP) 1992-05-27 EP claimed
US-4952402-A EDIBLE TASTE-MASKED DRUGS; MICROMATRIX ACTIVE MATERIAL COATED WITH NONTOXIC POLYMER; LIQUIDS; TABLETS ELAN CORPORATION, P.L.C. (IE) 1990-08-28 US claimed
EP-0148811-B1 PHARMACEUTICAL COMPOSITION LEJUS MEDICAL AKTIEBOLAG (SE) 1989-09-06 EP claimed
US-4780318-A DIFFERENT SOLUBILITIES AT DIFFERENT PHS LEJUS MEDICAL AKTIEBOLAG (SE) 1988-10-25 US claimed
EP-0189861-A2 Percutaneous absorption accelerator for ionic water-soluble medicine SHOWA DENKO KABUSHIKI KAISHA (JP) 1986-08-06 EP claimed
EP-0079522-B1 N-CARBOXYMETHYL(AMIDINO)LYSYL-PROLINE ANTIHYPERTENSIVE AGENTS MERCK & CO. INC. (US) 1986-05-07 EP claimed
EP-0148811-A1 Pharmaceutical composition LEJUS MEDICAL AKTIEBOLAG (SE) 1985-07-17 EP claimed
US-4281654-A Drug delivery system for controlled ocular therapy ALZA CORPORATION (US) 1981-08-04 US claimed